Nivolumab shows promise in advanced tumors with rare mutations

ESMO Virtual Congress 2020 featured a noteworthy study demonstrating that, in advanced tumors with the POLE gene's exonuclease domain affected by a pathogenic mutation (edPOLE), and a DNA mismatch repair mechanism (MMR) without problems, the nivolumab (Opdivo) immunotherapy as a single drug produced high response and disease control rates.
The POLE gene is responsible for producing an important protein involved in DNA repair and replication. Dr. Rousseau, a member of the research team, points out that edPOLE mutations occur rarely, and therefore the effectiveness of nivolumab had not been tested in patients with normally functioning MMR and edPOLE mutations. However, the researchers note that these mutations disrupt an important correction mechanism (proofreading) during DNA replication and cause a large accumulation of mutations, and that tumors with this genetic profile may be targets for immunotherapies.
In brief, the researchers examined the exonuclease domain of the POLE gene, whose importance in cancer treatment had previously been little known, and found rare mutations there. They then tested whether nivolumab was effective in patients with these mutations.
Study details
The anti-PD-1 antibody nivolumab was studied for its effectiveness in rare tumors in a phase 2 clinical trial in which patients received intravenous nivolumab every two weeks. This continued until disease progression or an unexpected side effect, for a maximum of 2 years.

Nivolumab produced better results in patients with pathogenic mutations
In 50% of the 16 enrolled patients, a pathogenic edPOLE mutation was identified, while mutations of uncertain significance were found in 3 patients and nonpathogenic mutations in 5 patients.
Measurements at week 12 showed an overall response rate of 38%, with 5 patients reported to have a partial response and 6 to have stable disease. In the pathogenic-mutation group, the overall response rate was 50%, and a disease control rate of 75% was found with two patients having stable disease. Of the 3 patients whose mutations were of uncertain significance, 2 responded to treatment and 1 had stable disease. In the group of 5 patients without a pathogenic mutation, disease progression was reported and two patients died.
The study measured progression-free survival (PFS) and overall survival. PFS in the group without a pathogenic mutation was 1.1 months, while in the group with pathogenic mutations or mutations of uncertain significance it was 5.6 months. Overall survival in the group without a pathogenic mutation was 5.3 months, while this figure was not yet available for the other group when the study was published.
Summary
This study of the anti-PD1 agent nivolumab in MMR-proficient tumors with POLE mutations represents the first clinical trial of its kind. The researchers conclude that nivolumab, for edPOLE mutant, MMR-proficient advanced cancer patients, appears promising , but that this may be limited to tumors with pathogenic mutations.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.